- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02042326
Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations (MAV-RAPA)
The aim of the study is to evaluate the efficacy and safety of sirolimus (oral form), to decrease the volume and symptoms due to superficial arteriovenous malformations (AVM).
Sirolimus has properties that reduce the activity of the immune system (immunosuppressant), to fight against the proliferation of cancer cells (anti- tumor) and also reduce the proliferation of blood vessels (anti -vascular). Sirolimus is primarily used in transplant patients to prevent organ transplant rejection. Many animal and laboratory studies were carried out and demonstrate in particular the activity of sirolimus on vessels. It is this anti- vascular effect that could help treat arteriovenous malformations.
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium
- Not yet recruiting
- UCL
-
-
-
-
-
Amiens, France, 80000
- Recruiting
- CHU Amiens
-
Bordeaux, France, 33000
- Not yet recruiting
- CHU Bordeaux
-
Dijon, France, 21000
- Recruiting
- CHU Dijon
-
Lille, France, 59000
- Not yet recruiting
- CHRU Lille
-
Lyon, France, 69000
- Recruiting
- HCL LYON
-
Marseille, France, 13000
- Not yet recruiting
- APHM
-
Montpellier, France, 34000
- Not yet recruiting
- CHU Montpellier
-
Nancy, France, 54000
- Not yet recruiting
- CHU Nancy
-
Nice, France, 06000
- Not yet recruiting
- CHU Nice
-
Paris, France, 75000
- Not yet recruiting
- APHP
-
Strasbourg, France, 67000
- Not yet recruiting
- CHU Strasbourg
-
Tours, France, 37000
- Not yet recruiting
- CHU Tours
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients (adults, adolescents and children older than 2 years), with arteriovenous malformation stage II + III or IV (according to Schöbinger's classification) : active or quiescent, marked or not by hemorrhagic phenomena.
- Patients (parents for minors) must sign a consent form established after clear information risks and expected benefits of the study.
- Patients (major and minor of childbearing age) must have effective contraception during the study period and continuing until 12 weeks after the end of treatment
- Negative pregnancy blood test for women of childbearing age.
Exclusion Criteria:
Chronic or acquired immunosuppression :
- patients with transplanted organ or who received a hematopoietic stem cell
- patient with congenital immunodeficiency
- Patients implanted with chronic active infection associated with hepatitis B , hepatitis C or HIV
- Pregnant or nursing woman.
- Allergy to macrolides
- Allergy to peanut or soya
- Hypersensitivity to " Sirolimus " or any of the excipients of the investigational product
- Contraindications to performing an MRI
- Leukopenia below 1 000 /mm3
- Thrombocytopenia lower to 80,000 /mm3
- Anemia with Hb < 9 g/dl
- Elevated transaminase > 2.5 N
- History of cancer less than two years before the inclusion
- Surgery older than 2 months before inclusion
- Active infection (viral and bacterial ) on the date of inclusion
- Hypercholesterolemia > 7 mmol / l despite appropriate medical treatment
- Hyperlipidemia > 2 mmol / l despite appropriate medical treatment
- Uncontrolled diabetes
- Patients unable to follow a clinical study
- Major under guardianship, persons deprived of their liberty
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sirolimus treatment
Patients will receive sirolimus (Rapamune). The dose should be adjusted to obtain a residual plasma rate of 8 to 12 ng/ml in 4 weeks. This serum level will be maintained throughout the duration of the study in the absence of side effects. In case of intolerance that do not justify the discontinuation of treatment, the dose may be reduced by maintaining a serum level greater than 3 ng/ml. The starting dose will be 2 mg per day, and will be adapted every week for one month. The preferred dosage form is tablet form. To prevent common side effects in early treatment, corticosteroids based prednisolone (SOLUPRED) will be established at a dose of 0.5 mg/ kg/day for the first week of treatment. |
For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment efficacy at M12
Time Frame: After 12 months of treatment
|
The efficacy of treatment is a composite criteria based on:
|
After 12 months of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment efficacy at M3
Time Frame: After 3 months of treatment
|
After 3 months of treatment
|
|
Treatment efficacy at M6
Time Frame: After 6 months of treatment
|
After 6 months of treatment
|
|
Treatment efficacy at M9
Time Frame: After 9 months of treatment
|
After 9 months of treatment
|
|
Treatment tolerability
Time Frame: One year
|
Number and description of serious advent events
|
One year
|
Treatment Impact on Quality of life
Time Frame: Before treatment initiation and after 12 months of treatment
|
Quality of life will be assessed before and at the end of the first year of treatment using a questionnaire given to patients.
There is no questionnaire specifically tailored to vascular malformations in the literature.
Thus the investigators adapted a document based on an evaluation of the quality of life for survivors of burn injury.
|
Before treatment initiation and after 12 months of treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Cardiovascular Abnormalities
- Neoplasms, Vascular Tissue
- Vascular Malformations
- Congenital Abnormalities
- Hemangioma
- Arteriovenous Malformations
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- PHRCN10-PR-DEVAUCHELLE
- 2011-000321-69 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arteriovenous Malformations
-
Centre hospitalier de l'Université de Montréal...Active, not recruitingUnruptured Brain Arteriovenous Malformation | Ruptured Brain Arteriovenous Malformation | Arteriovenous Malformations, CerebralCanada, France
-
University of ArkansasGenentech, Inc.RecruitingArteriovenous Malformations (Extracranial)United States
-
Fondation Ophtalmologique Adolphe de RothschildRecruitingCerebral Arteriovenous Malformations | Ruptured or Unruptured Cerebral Arteriovenous MalformationsFrance
-
Embo-Flüssigkeiten A.G.Active, not recruitingCerebral Arteriovenous MalformationFrance, Denmark, Germany, Belgium, Italy
-
Fondation Ophtalmologique Adolphe de RothschildNot yet recruiting
-
Medtronic Neurovascular Clinical AffairsCompletedCerebral Arteriovenous MalformationsFrance
-
Microvention-Terumo, Inc.ClinSearchTerminatedCerebral AV MalformationUnited Kingdom, Spain, Denmark, France, Sweden
-
yuanli ZhaoPeking University International HospitalRecruitingCerebral Arteriovenous MalformationChina
-
Dr. Markus Alfred MöhlenbruchUniversity Hospital Schleswig-HolsteinCompletedDural Arteriovenous FistulaGermany
-
Beijing Tiantan HospitalNot yet recruitingCerebral Arteriovenous MalformationChina
Clinical Trials on Sirolimus
-
Aadi Bioscience, Inc.Approved for marketingTSC1 | TSC2 | PEComa, Malignant | mTOR Pathway Abberation
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
Stefan Schieke MDWithdrawnCutaneous T-cell Lymphoma (CTCL)United States
-
Aadi Bioscience, Inc.CompletedHigh Grade Recurrent Glioma and Newly Diagnosed GlioblastomaUnited States
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosisUnited States
-
The University of Texas Health Science Center,...Society for Pediatric DermatologyCompletedTuberous Sclerosis | Neurofibromatoses | Neurofibroma | AngiofibromaUnited States
-
Xijing HospitalAir Force Military Medical University, China; Shanghai MicroPort Medical (Group)... and other collaboratorsUnknown
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat IndiaCompleted
-
Shanghai Jiao Tong University School of MedicineUnknownCoronary Artery DiseaseChina
-
Paul S Teirstein, MDCordis CorporationCompletedCoronary Artery Disease | Coronary Thrombosis | Coronary RestenosisUnited States